Last reviewed · How we verify

NCT06206590

Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates

Status unknown Last updated 16 January 2024
What this trial tests

trial testing Whole-proteomic assay in Neonatal Disease in 116 participants. Status unknown.

Timeline
1 November 2023
Primary endpoint
1 September 2025
31 December 2025

Quick facts

Lead sponsorGuangdong Women and Children Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment116
Start date1 November 2023
Primary completion1 September 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangdong Women and Children Hospital

Who can join

Adults 1 Day to 1 Day, any sex, with Neonatal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1\. Explore 32 weeks of premature infants or maternal pregnancy infection of newborn septic shock maternal influence factors. 2. Through maternal blood samples before delivery and labor cord blood sample screening and septic shock related proteomics analysis, explore the relationship between the difference protein and septic shock and prognosis, and explore the pathway mechanism, in order to prevent and reduce the occurrence of septic shock in premature infants

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neonatal Disease

Currently open trials in the same condition.

Other Guangdong Women and Children Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06206590.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing